FMP

FMP

Enter

DRRX - DURECT Corporat...

photo-url-https://images.financialmodelingprep.com/symbol/DRRX.png

DURECT Corporation

DRRX

NASDAQ

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

0.873 USD

-0.0469 (-5.37%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Dr. James E. Brown D.V.M.

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

exchange

NASDAQ

Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers...

CIK

0001082038

ISIN

US2666055007

CUSIP

266605104

Address

10260 Bubb Road

Phone

408 777 1417

Country

US

Employee

48

IPO Date

Sep 28, 2000

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

DRRX Financial Summary

CIK

0001082038

Exchange

NASDAQ

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

266605104

ISIN

US2666055007

Country

US

Price

0.87

Beta

1.13

Volume Avg.

71.36k

Market Cap

27.1M

Shares

-

52-Week

0.48-1.88

DCF

-0.94

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.3

P/B

-

Website

https://www.durect.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest DRRX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep